FY2022 Q3 Financial and R&D Update
Major R&D Pipeline: 3ADCs
(US/EU/Asia) HER2+ BC 2L+/1L
DESTINY-Breast07
Phase 1
(JP/US) NSCLC, TNBC, BC*1, SCLC, GC,
urothelial, esophageal, prostate, etc.
TROPION-PanTumor01
(CN) NSCLC, TNBC
TROPION-PanTumor02
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(CN) HER2+ GC 3L
DESTINY-Gastric06
(US/EU/Asia) HER2 low BC
Chemo naïve/ post chemo
DESTINY-Breast08
(JP/US/EU/Asia) HER2+ GC combo, 2L+/1L
DESTINY-Gastric03
(EU/Asia) HER2+ NSCLC
(durvalumab combo) 1L
DESTINY-Lung03
(US/EU) BC, bladder
(nivolumab combo)
(US/EU) BC, NSCLC
(pembrolizumab combo)
(US/EU/Asia) solid tumors.
(AZD5305 combo)
PETRA
(JP/US/EU/Asia) NSCLC (w/o AGA,
pembrolizumab combo)
TROPION-Lung02
(UP/US/EU) NSCLC (w/o AGA,
durvalumab combo)
TROPION-Lung04
(JP/US/EU/Asia) solid tumors
(AZD5305 combo)
PETRA
(UP/US/EU/Asia) NSCLC
(JP/US) EGFR mutated NSCLC
(osimertinib combo)
(JP/US) HER3+ BC
(JP/US/EU) HER2+ or HER2 mutant NSCLC
2L+
DESTINY-Lung01
(JP/US/EU/Asia) HER2 mutant NSCLC 2L+
DESTINY-Lung02
(CN) HER2 mutant NSCLC 2L+
DESTINY-Lung05
(US/EU/Asia) NSCLC
(durvalumab combo) 2L+
HUDSON
(JP/US/EU) HER2+ CRC 3L
DESTINY-CRC01
(JP/US/EU/Asia) HER2+ CRC 3L
DESTINY-CRC02
Phase 2
(JP/US/EU/Asia) endometrial, ovarian, CRPC,
GC, CRC combo
TROPION-PanTumor03
(JP/US/EU/Asia) NSCLC (w/ AGA)
TROPION-Lung05
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(JP/US/EU/Asia) EGFR mutated
NSCLC (osimertinib combo) 2L
ORCHARD
(UP/US/EU/Asia) EGFR mutated
NSCLC 3L
HERTHENA-Lung01
Phase 3
(JP/US/EU/Asia) HER2+ BC 3L
DESTINY-Breast02
As of Jan 2023
(CN) HER2+ BC 2L
DESTINY-Breast03
Filed
(JP/US/EU/Asia) HER2+ BC
adjuvant*2
DESTINY-Breast05
(JP/US/EU/Asia) HER2 low BC
chemo naïve
DESTINY-Breast06
(JP/US/EU/Asia) HER2+ BC 1L
DESTINY-Breast09
(JP/CN) HER2 low BC
post chemo
DESTINY-Breast04
(JP/EU) HER2 mutant NSCLC 2L+
DESTINY-Lung01/Lung02
(JP/US/EU/Asia) HER2+ BC
neoadjuvant
DESTINY-Breast11
(JP/EU/Asia) HER2+ GC 2L
DESTINY-Gastric04
ENHERTUⓇ
Dato-DXd
HER3-DXd
(JP/US/EU/Asia)
HER2 mutant tumor
DESTINY-Pan Tumor01
(US/EU/Asia)
HER2 expressing tumor
DESTINY-PanTumor02
Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
Breakthrough Designation (US)
*1 HR+, HER2 low or negative BC
Orphan drug designation (JP)
*2 Adjuvant therapy for HER2 positive breast cancer patients with residual invasive disease following neoadjuvant therapy
*3 Adjuvant therapy for TNBC patients with residual invasive disease following neoadjuvant therapy
AGA: actionable genomic alterations, BC: breast cancer, CRPC: castration-resistant prostate cancer, CRC: colorectal cancer,
GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer
(JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or
exon 20 mutation) 1L
DESTINY-Lung04
(UP/US/EU/Asia) NSCLC 2/3L
TROPION-Lung01
(JP/US/EU/Asia) non-squamous NSCLC (w/o
AGA, pembrolizumab combo) 1L
TROPION-Lung07
(JP/US/EU/Asia) NSCLC (w/o AGA,
pembrolizumab combo) 1L
TROPION-Lung08
(JP/US/EU/Asia) BC*1 2/3L
TROPION-Breast01
(UP/US/EU/Asia) TNBC 1L
TROPION-Breast02
(JP/US/EU/Asia) TNBC (mono or
durvalumab combo) adjuvant*³
TROPION-Breast03
(JP/US/EU/Asia) EGFR mutated
NSCLC 2L
HERTHENA-Lung02
Daiichi-Sankyo
37View entire presentation